Dalzanemdor, formerly SAGE-718, fails to aid cognition in Phase 2 trial
Sage Therapeutics’ dalzanemdor, formerly known as SAGE-718, an investigational oral medication for mild cognitive impairment (MCI) due to…
Articles by Steve Bryson, PhD
VPS13C defects disrupt lysosomes in dopamine neurons
Defects in the VPS13C protein, which have been linked to early-onset Parkinson’s disease, disrupt the function of lysosomes, the…
Neuroinflammation tied to mood disturbance in early Parkinson’s
New study findings strengthen scientists’ belief that neuroinflammation — an inflammatory response in the central nervous system — is linked…
Hydrogel can boost survival of precursor nerve cells to brain
Encapsulating precursor nerve cells in a collagen hydrogel can enhance the efficacy of stem cell transplantation to the brain, a…
Mesdopetam may be novel treatment for Parkinson’s psychosis
Mesdopetam (IRL790), an investigational therapy for levodopa-induced dyskinesia in Parkinson’s disease, was found to reduce signs of psychosis in…
New evidence supports causal link between air pollutant, Parkinson’s
A new population study has provided evidence of a potential causal link between exposure to an air pollutant called fine…
ND0612 allows for better on time than oral levodopa: Phase 3 trial
Note: This story was updated March 21, 2024, to correct that NeuroDerm is a subsidiary of Mitsubishi Tanabe Pharma…
Nuplazid Parkinson’s medication also found to improve quality of life
Four months of daily Nuplazid (pimavanserin), an approved oral therapy for psychosis associated with Parkinson’s disease, was also…
New UK trial to test Olatec’s dapansutrile in early Parkinson’s
Olatec Therapeutics will launch a Phase 2 clinical trial in the U.K. to investigate the potential of oral dapansutrile…
Loss of dopamine nerve cells affects opposite side movement sequences
The selective loss of dopamine-producing nerve cells in one side of the brain of mice, to mimic Parkinson’s disease,…